Who makes BMS-981164?

BMS-981164 is developed by Bristol-Myers Squibb.

Last reviewed 2026-04-19 · How we verify

BMS-981164

Bristol-Myers Squibb · Phase 1 active Biologic

At a glance

Generic name	BMS-981164
Also known as	IL-31 mAB
Sponsor	Bristol-Myers Squibb
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BMS-981164 CI brief — competitive landscape report
BMS-981164 updates RSS · CI watch RSS
Bristol-Myers Squibb portfolio CI